All Type of News
Legal war for the sufferers of Dana Clinic crisis starts with submission of complaint
Followed by the application of the dispute settlement to the Korea Medical Dispute and Arbitration Agency, the sufferers from the so-called Dana Clinic crisis – mass infection of hepatitis C caused by injection reuses...
Despite depression of domestic market, last year’s pharmaceutical sales reached KRW 12.6 trillion
Due to the depression of the domestic market, the sales of pharmaceutical products are expected to grow 3.3% last year compared to the year before.
Shinhan Investment Corp. estimated the last year’s pharmaceutical sa...
Green Cross Labcell starts world’s first commercialization of NK cell treatmentAn anticancer therapy, which uses other healthy people’s immune cells not the ones of cancer patients, is expected to be commercialized within in a couple of years for the first...
|
‘3rd Global Pharmaceutical Fund’ to be completed late January
Development of the ‘3rd Global Pharmaceutical Fund,’ which will become the base of the pharmaceutical and medical package expansion, is expected to be completed late January.
In order to support the foreign expansion...
Domestic supply of GSK’s meningitis, ‘Hiberix,’ suspended‘Hiberix,’ a meningitis vaccine, has been suspended in the domestic supply.
GSK, the supplier of the drug, decided to suspend the supply of Hiberix as adopting ‘Vaxem-Hib,’ ano...
|
Pharmaceutical companies, “The next target is the ‘prostatism’ market”
As a target for the next male-specific disease, pharmaceutical companies have focused on ‘prostatism.’
Prostatism, a well-known disease for the middle-aged and aged, is a disease caused as the size of prostate enlarg...
First domestically developed/manufactured oral cholera vaccine acquires WHO PQ
On the 12th, the International Vaccine Institute(IVI) and Eubiologics announced ‘Euvichol,’ an inactivated oral cholera vaccine manufactured by Eubiologics, has recently acquired the prequalification(PQ) by the World ...
“We decided to improve the multinational companies’ low distribution cost to the domestic level”
The pharmaceutical distribution industry, which had been busy interrupting the multinational pharmaceutical companies’ pharmaceutical distribution cost reduction so far, started to take actions to raise the cost.
The...
Boehringer’s SGLT-2 complex, Synjardy, is expected to be approved this monthThe complex of the Boehringer Ingelheim’s SGLT-2-inhibitor antidiabetic agent, Jardiance(empagliflozin), and metformin will enter the domestic market this month at the fastest.
...
|
Will Boehringer give Yuhan Corporation ‘Jardiance’?
As ‘Jardiance(generic name: empagliflozin),’ a SGLT-2 inhibitor, is anticipated to receive the insurance benefit in the 1st half of the year at the latest, the industry has paid attention on which company will become ...
